Vor Biopharma (VOR) Total Current Liabilities (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Total Current Liabilities of $16.1 million for Q1 2026, down 3.89% year-over-year from $16.7 million in Q1 2025, and down 36.13% quarter-over-quarter from $25.2 million in Q4 2025.
Vor Biopharma (VOR) Total Current Liabilities (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Total Current Liabilities for 7 consecutive years, with $16.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 3.89% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (down 3.89% YoY), while the FY2025 annual figure was $25.2 million, up 35.24% from the prior year.
- Total Current Liabilities retreated to $16.1 million in Q1 2026 per VOR's latest filing, from $25.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $58.8 million in Q2 2025 and bottomed at $11.1 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $18.0 million across 5 years, with a median of $15.4 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities sank 30.68% — and 2025, when it soared 325.86%.
- Vor Biopharma's Total Current Liabilities stood at $13.1 million in 2022, then gained by 18.7% to $15.6 million in 2023, then increased by 19.52% to $18.6 million in 2024, then jumped by 35.24% to $25.2 million in 2025, then tumbled by 36.13% to $16.1 million in 2026.
- Business Quant data shows VOR's Total Current Liabilities at $16.1 million in Q1 2026, $25.2 million in Q4 2025, and $18.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 24.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.81 Mn |
| Mar 31, 2026 | 16.08 Mn |
| Dec 31, 2025 | 25.17 Mn |
| Sep 30, 2025 | 18.84 Mn |
| Jun 30, 2025 | 58.77 Mn |
| Mar 31, 2025 | 16.73 Mn |
| Dec 31, 2024 | 18.61 Mn |
| Sep 30, 2024 | 14.35 Mn |
| Jun 30, 2024 | 13.80 Mn |
| Mar 31, 2024 | 13.21 Mn |
| Dec 31, 2023 | 15.57 Mn |
| Sep 30, 2023 | 15.39 Mn |
| Jun 30, 2023 | 12.72 Mn |
| Mar 31, 2023 | 12.58 Mn |
| Dec 31, 2022 | 13.12 Mn |
| Sep 30, 2022 | 11.10 Mn |
| Jun 30, 2022 | 12.26 Mn |
| Mar 31, 2022 | 18.15 Mn |
| Dec 31, 2021 | 10.15 Mn |
| Sep 30, 2021 | 9.21 Mn |